Coegin Pharma AB (NGM:COEGIN)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.110
+0.100 (3.32%)
At close: Jul 22, 2025

Coegin Pharma AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cost of Revenue
0.010.020.02---
Gross Profit
-0.01-0.02-0.02---
Selling, General & Admin
19.8320.2925.2134.9431.9148.6
Other Operating Expenses
-0.030.01-0.43-2.97-4.74-2.34
Operating Expenses
22.8223.3227.834.6927.1846.28
Operating Income
-22.84-23.33-27.82-34.69-27.18-46.28
Interest Expense
-0.01-0.46-0.05-0.22--
Interest & Investment Income
0.0100.020.01-0.04
Earnings From Equity Investments
-0.05-0.05----
Currency Exchange Gain (Loss)
0.060.06-0.14-0.330.04-0.01
Pretax Income
-22.83-23.78-27.98-35.24-27.15-46.24
Net Income
-22.83-23.78-27.98-35.24-27.15-46.24
Net Income to Common
-22.83-23.78-27.98-35.24-27.15-46.24
Shares Outstanding (Basic)
22199761
Shares Outstanding (Diluted)
22199761
Shares Change (YoY)
131.32%105.53%34.42%15.36%354.98%-
EPS (Basic)
-1.02-1.26-3.04-5.14-4.59-35.39
EPS (Diluted)
-1.03-1.26-3.04-5.14-4.59-35.39
EBITDA
-19.82-20.32-24.79-31.97-27.17-46.25
D&A For EBITDA
3.023.023.022.720.010.02
EBIT
-22.84-23.33-27.82-34.69-27.18-46.28
Revenue as Reported
0.070.060.573.134.762.34
Updated Jan 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.